AI-generated summary
The authors report an open-label study of transcranial photobiomodulation given twice weekly for 8 weeks to 10 adults with high-functioning autism spectrum disorder. They found significant reductions in Social Responsiveness Scale-2 scores and reported mild, transient side effects in three participants. The abstract notes the single-group, open-label design and small sample, and calls for further research.
- Participants
- 10
- Who or what was studied
- Adults aged 18 to 59 with high-functioning autism spectrum disorder; 10 completers (9 males, mean age 30.0 years)
- Limits stated in the abstract
- The study used an open-label single-group design with a small sample of 10 completers and no control group.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Transcranial photobiomodulation, Photobiomodulation, Autism, Insomnia. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.